Nxera Pharma Co (FRA:JSS) Debt-to-Asset : 0.45 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Nxera Pharma Co Debt-to-Asset?

Nxera Pharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €41.5 Mil. Nxera Pharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €380.0 Mil. Nxera Pharma Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was €940.6 Mil. Nxera Pharma Co's debt to asset for the quarter that ended in Dec. 2024 was 0.45.

Nxera Pharma Co Debt-to-Asset Historical Data

The historical data trend for Nxera Pharma Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Debt-to-Asset Chart

Nxera Pharma Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.22

0.30

0.47

0.45

Nxera Pharma Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.47	0.48	0.45	0.46	0.45

Competitive Comparison of Nxera Pharma Co's Debt-to-Asset

For the Biotechnology subindustry, Nxera Pharma Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nxera Pharma Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Nxera Pharma Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Nxera Pharma Co's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(41.537	+	380.04)	/	940.619
	=	0.45

Nxera Pharma Co's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(41.537	+	380.04)	/	940.619
	=	0.45

Nxera Pharma Co (FRA:JSS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Nxera Pharma Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nxera Pharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (FRA:JSS) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

4565:Japan JSS:Germany

Address

Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052

Website

https://www.nxera.life

Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).

Nxera Pharma Co Headlines

No Headlines